GlassScriptPhysician profile
Denise Deveranez
NPI 1659409043
$1,412.07
in general payments reported to CMS, 2019-2025
9 companies · $82.15 in 2025
The $82.15 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.27 · 2020: $66.25 · 2021: $87.95 · 2022: $22.46 · 2023: $225 · 2024: $896 · 2025: $82.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $600.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $240.76 | 2020-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $190.26 | 2020-2024 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $137.94 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $102.92 | 2023-2024 | |
| Glaxosmithkline, LLC. | $66.58 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $32.74 | 2024 | |
| Dynavax Technologies Corporation | $21.98 | 2024 | Heplisav-B |
| Amgen INC. | $18.14 | 2024 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Deveranez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.